Remix Therapeutics Appoints Maria Koehler, M.D., Ph.D., as an Independent Board Director
Remix Therapeutics Appoints Maria Koehler, M.D., Ph.D., as an Independent Board Director
Dr. Koehler brings over 20 years of oncology drug development leadership experience to Remix's Board of Directors
Koehler博士擁有20多年的腫瘤藥物開發領導經驗，被任命爲Remix的董事會獨立董事。
WATERTOWN, Mass., June 18, 2024 /PRNewswire/ -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying drivers of disease, today announced the appointment of Maria Koehler, M.D., Ph.D., as an independent director to Remix's Board of Directors.
馬里亞·科勒博士（Maria Koehler）於2024年6月18日被任命爲Remix Therapeutics (Remix)的獨立董事。Remix Therapeutics是一家處於臨床階段的生物技術公司，開發小分子療法以調節RNA加工，並解決疾病的根本原因。
"Dr. Koehler's industry knowledge and wealth of experience will prove invaluable as we advance our pipeline of RNA processing modulators, including our first-in-class lead program REM-422," said Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix. "We look forward to partnering with Dr. Koehler as Remix enters this exciting new era and continues progressing in the clinic."
“Koehler博士的行業知識和豐富經驗將在我們推進RNA加工調節劑產品線方面發揮寶貴作用，包括我們首創的REM-422領先項目，”Remix聯合創始人兼首席執行官Peter Smith博士表示。 “我們期待與Koehler博士合作，讓Remix進入這個激動人心的新時代，並繼續在臨床中取得進展。”
Dr. Koehler brings over 20 years of experience leading clinical and regulatory strategy operations for biotechnology and pharmaceutical companies focused on oncology research and development. She is currently the Chief Medical Officer of Repare Therapeutics, a clinical-stage precision oncology company. Dr. Koehler has also held executive and medical leadership roles at numerous companies, including Pfizer, AstraZeneca, Bicycle Therapeutics, and GlaxoSmithKline. Additionally, Dr. Koehler has served as the clinical director of Bone Marrow Transplantation at University Hospital in Pittsburgh and the director of the Bone Marrow Transplant Program and associate professor at St. Christopher's Hospital in Philadelphia. She is a board-certified hematology/oncology physician, holding an M.D. and Ph.D. from the Silesian School of Medicine in Katowice, Poland. Dr. Koehler currently serves as an independent director on the board of directors at Ikena Oncology and Abdera Therapeutics.
Koehler博士擁有20多年的臨床和監管策略運營領導經驗，專注於生物技術和製藥公司的腫瘤研究和開發。她目前是Repere Therapeutics的首席醫學官，該公司是一家臨床階段的精準腫瘤學公司。Koehler博士還曾在Pfizer、阿斯利康、bicycle therapeutics、葛蘭素史克等公司擔任高管和醫學領導職務。此外，Koehler博士還在匹茲堡大學醫院擔任骨髓移植臨床主任，以及費城聖克里斯托弗醫院骨髓移植項目主任和副教授。她是一名持有波蘭卡托維茲西里西亞醫學院（Silesian School of Medicine）醫學博士學位和博士學位的血液學/腫瘤學醫師。Koehler博士目前還在Ikena Oncology和Abdera Therapeutics的董事會擔任獨立董事。
"I am delighted to join the Remix team during this exciting time as we see the emerging therapeutic potential of reprogramming RNA processing," said Dr. Koehler. "I look forward to working with Remix leadership and fellow board members to drive this innovative science forward."
“我很高興在這個激動人心的時候加入Remix團隊，看到重新編程RNA加工的療效潛力。”Koehler博士說。“我期待與Remix領導層和其他董事會成員合作，推動這種創新科學前進。”
About Remix Therapeutics
Remix Therapeutics is a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease. The REMaster technology platform facilitates RNA processing pattern identification, leveraging these learnings to modulate gene expression. Remix's innovative therapeutic approach has the potential to alter the way genes are read from the genome, to correct, enhance, or eliminate the gene message, thereby addressing disease drivers at their origin. For more information visit .
關於Remix Therapeutics
Remix Therapeutics是一家處於臨床階段的生物技術公司，開發新型小分子療法，旨在重新編程RNA加工並治療疾病。REMaster技術平台有助於RNA加工模式識別，利用這些學習結果調節基因表達。Remix創新的治療方法有可能改變基因從基因組中讀取的方式，從而糾正、增強或消除基因信息，因此解決疾病的根源。了解更多信息，請訪問.
SOURCE Remix Therapeutics
源互聯治療
譯文內容由第三人軟體翻譯。